1 week Ago By Defense World Staff
Equities research analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals ( NASDAQ:TTNP – Get Free Report ) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Up 1.3 % Shares of Titan Pharmaceuticals stock opened at $3.23 on Friday.
Titan Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $14.80.
The company has a 50 day moving average price of $3.72 and a 200 day moving average price of $4.97.
Titan Pharmaceuticals ( NASDAQ:TTNP – Get Free Report ) last announced its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also Five stocks we like better than Titan Pharmaceuticals Differences Between Momentum Investing and Long Term Investing Insiders Are Selling, But These 3 Stocks Are Must-Buys Airline Stocks – Top Airline Stocks to Buy Now Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge Trading Halts Explained Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’ Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
